Anthony S. Gibney

Executive Vice President & Chief Business Officer at Achillion Pharmaceuticals Inc.

Anthony S. Gibney

Anthony S. Gibney

Executive Vice President & Chief Business Officer at Achillion Pharmaceuticals Inc.

Overview
RelSci Relationships

742

Number of Boards

2

Birthday

1971

Age

48

Relationships
RelSci Relationships are individuals Anthony S. Gibney likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at InflaRx NV

Relationship likelihood: Strong

Chief Executive Officer & Founder at InflaRx NV

Relationship likelihood: Strong

Chief Scientific Officer & Founder at InflaRx NV

Relationship likelihood: Strong

Senior Investment Manager at bm-t beteiligungsmanagement thüringen GmbH

Relationship likelihood: Strong

Chief Financial Officer at MorphoSys AG

Relationship likelihood: Strong

Board Secretary & Deputy General Manager at Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Relationship likelihood: Strong

Partner at GIG Ltd.

Relationship likelihood: Strong

Chair, San Diego Emerging Companies Practice at Latham & Watkins LLP

Relationship likelihood: Strong

Director, President & Chief Executive Officer at Achillion Pharmaceuticals Inc.

Relationship likelihood: Average

Executive Director, Investor Relations at Achillion Pharmaceuticals Inc.

Relationship likelihood: Average

Paths to Anthony S. Gibney
Potential Connections via
Relationship Science
You
Anthony S. Gibney
Executive Vice President & Chief Business Officer at Achillion Pharmaceuticals Inc.
Education
Class of 1993

Yale University is an American private Ivy League research university located in New Haven, Connecticut. Founded in 1701 in the Colony of Connecticut, the university is the third-oldest institution of higher education in the United States.

Career History
Professional
Prior

Merrill Lynch & Co., Inc. provided wealth management, securities trading and sales, corporate finance and investment banking services. Merrill Lynch was a global trader and underwriter of securities and derivatives across a range of asset classes and serve as a strategic advisor to governments, institutions and individuals worldwide. The company was founded in 1913 and was headquartered in Charlotte, NC.

Managing Director
2009 - 2017

Founded by Jeffrey Leerink in 1995, Leerink Swann LLC, formerly Leerink Swann & Co., is a full-service healthcare-focused investment banking firm that offers institutional sales, equity research, institutional trading, corporate finance and asset management services. The firm's investment banking activities include private placements, public offerings, private investment in public equity (PIPEs), registered direct offerings (RDOs and mergers & acquisitions.Leerink Swann's investment perspectives are driven by proprietary insights from MEDACorp., a network of over 35,000 physicians, researchers and healthcare professionals in North America, Europe, Asia and around the world with expertise in: clinical medicine, basic sciences, biomedical research, regulatory affairs, intellectual property, public health and policy, managed care, pharmacy management/pharmacy benefits management, healthcare administration, healthcare facilities, healthcare information technology, allied health services and healthcare consulting.Leerink Swann offers equity healthcare research coverage of the following areas: biotechnology, life science tools and diagnostics, pharmaceuticals, medical supplies and devices and healthcare services. The firm is also a market maker in over 350 NASDAQ equities.

Managing Director-Global Healthcare Group
1999 - 2009

Merrill Lynch is one of the world’s premier providers of wealth management, securities trading and sales, corporate finance and investment banking services. More than 60,000 professionals in 40 countries combine local market expertise with Merrill Lynch’s substantial global product resources, technology and capital.

Boards & Committees
Member, Board of Directors
2018 - 2019

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Director
Prior

InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany.

Political Donations
Transactions
Details Hidden

Immunogen Inc. issued USD Common Stock

Details Hidden

ArQule, Inc. issued Common Stock

Details Hidden

Amicus Therapeutics, Inc. issued Common Stock

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Anthony S. Gibney. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Anthony S. Gibney's profile does not indicate a business or promotional relationship of any kind between RelSci and Anthony S. Gibney.